	US 11,813,235 B2
	Guanfacine as an anti-virulence agent
Mohammad R. Seyedsayamdost, Princeton, NJ (US); Bethany K. Okada, San Diego, CA (US); and Anran Li, Plainsboro, NJ (US)
Assigned to THE TRUSTEES OF PRINCETON UNIVERSITY, Princeton, NJ (US)
Filed by The Trustees of Princeton University, Princeton, NJ (US)
Filed on Mar. 20, 2020, as Appl. No. 16/824,968.
Claims priority of provisional application 62/822,519, filed on Mar. 22, 2019.
Prior Publication US 2020/0297669 A1, Sep. 24, 2020
Int. Cl. A61K 31/155 (2006.01); A61P 31/04 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/155 (2013.01) [A61P 31/04 (2018.01); A61K 45/06 (2013.01)]

10 Claims

1. A method for treating a patient with an infection from Pseudomonas aeruginosa via virulence factor inhibition, comprising steps of:

administering to the patient a therapeutically effective dose of guanfacine, an analog or derivative of guanfacine, or a pharmaceutically acceptable salt thereof,

wherein the analog or derivative of guanfacine has the structure R¹—R²—CONH—R³, where R¹is an optionally substituted phenyl or benzyl group, R²is a methylene unit or a C1-C6 alkyl group that is saturated or unsaturated, and R³is a carboxamidine.